2023 Q4 Form 10-K Financial Statement

#000149315223037178 Filed on October 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q2 2023
Revenue $5.000K $0.00 $25.00K
YoY Change -16.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $186.7K -$248.3K $560.8K
YoY Change -96.48%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $186.7K $216.6K $1.026M
YoY Change -13.24% -93.94%
Operating Profit -$181.7K -$1.001M
YoY Change -15.56% -94.08%
Interest Expense $236.6K -$112.0K $934.9K
YoY Change 65.75% -41.3%
% of Operating Profit
Other Income/Expense, Net -$1.530M -$1.064M -$4.609M
YoY Change 280.88% 8.32%
Pretax Income -$1.712M -$1.392M -$5.609M
YoY Change -73.48%
Income Tax
% Of Pretax Income
Net Earnings -$1.712M -$1.392M -$5.609M
YoY Change 177.49% -73.48%
Net Earnings / Revenue -34238.76% -22436.58%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 42.71B shares 37.06B shares 34.46B shares
Diluted Shares Outstanding 42.68B shares 34.46B shares

Balance Sheet

Concept 2023 Q4 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.45K $20.19K $20.19K
YoY Change -70.5%
Cash & Equivalents $29.44K $19.77K $19.77K
Short-Term Investments $10.00 $420.00 $420.00
Other Short-Term Assets $120.6K $241.4K $241.4K
YoY Change -73.33% -33.92% -33.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $150.1K $261.6K $261.6K
YoY Change -68.18% -39.69% -39.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $33.11K $32.60K $32.60K
YoY Change -9.85%
Other Assets $0.00
YoY Change
Total Long-Term Assets $33.11K $32.60K $32.61K
YoY Change -10.5% -9.84% -9.82%
TOTAL ASSETS
Total Short-Term Assets $150.1K $261.6K $261.6K
Total Long-Term Assets $33.11K $32.60K $32.61K
Total Assets $183.2K $294.2K $294.2K
YoY Change -63.99% -37.4% -37.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $618.4K $616.2K $616.3K
YoY Change 1.13% 0.07% 0.07%
Accrued Expenses $2.346M $1.485M $1.485M
YoY Change 96.63% 59.47% 59.47%
Deferred Revenue $1.103M $1.079M
YoY Change 67.01% 62.16%
Short-Term Debt $2.260M $1.165M $1.462M
YoY Change 137.63% 2.05%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.730M $8.516M $8.516M
YoY Change 18.12% 21.43% 21.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.730M $8.516M $8.516M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $8.730M $8.516M $8.516M
YoY Change 18.12% 21.43% 21.43%
SHAREHOLDERS EQUITY
Retained Earnings -$82.02M -$77.32M
YoY Change 10.61% 7.81%
Common Stock $74.48M $72.19M
YoY Change 9.68% 9.67%
Preferred Stock
YoY Change
Treasury Stock (at cost) $44.17K $44.17K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity -$8.546M -$8.222M -$8.222M
YoY Change
Total Liabilities & Shareholders Equity $183.2K $294.2K $294.2K
YoY Change -63.99% -37.4% -37.39%

Cashflow Statement

Concept 2023 Q4 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$1.712M -$1.392M -$5.609M
YoY Change 177.49% -73.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$884.9K -$1.018M -$1.572M
YoY Change 1.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $506.4K $3.560K
YoY Change -99.13%
Cash From Investing Activities $0.00 $506.4K $3.557K
YoY Change -99.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.541M
YoY Change 7603.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 910.6K 534.8K $1.521M
YoY Change 37.34%
NET CHANGE
Cash From Operating Activities -884.9K -1.018M -$1.572M
Cash From Investing Activities 0.000 506.4K $3.557K
Cash From Financing Activities 910.6K 534.8K $1.521M
Net Change In Cash 25.67K 23.63K -$48.13K
YoY Change 75.35%
FREE CASH FLOW
Cash From Operating Activities -$884.9K -$1.018M -$1.572M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000704172
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 PHIL Common Stock To Be Issued
CommonStockToBeIssued
usd
CY2023 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#InvestmentAdvisoryManagementAndAdministrativeServiceMember
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#InvestmentAdvisoryManagementAndAdministrativeServiceMember
CY2022 PHIL Fund In Transit
FundInTransit
usd
CY2022 PHIL Proceeds From Financing Loans
ProceedsFromFinancingLoans
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
PHI GROUP, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023 dei Entity File Number
EntityFileNumber
001-38255-NY
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0114535
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2323 Main Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92614
CY2023 dei City Area Code
CityAreaCode
714
CY2023 dei Local Phone Number
LocalPhoneNumber
465-4365
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
PHIL
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42705215171 shares
CY2023 dei Auditor Firm
AuditorFirmId
6662
CY2023 dei Auditor Name
AuditorName
M.S. Madhava Rao
CY2023 dei Auditor Location
AuditorLocation
Bengaluru, India
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19765 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67896 usd
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
420 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
546 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
241426 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
365360 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
261611 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
433802 usd
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
32604 usd
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
36161 usd
CY2023Q2 us-gaap Assets
Assets
294215 usd
CY2022Q2 us-gaap Assets
Assets
469963 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
616245 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
615805 usd
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1624775 usd
CY2022Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1574775 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1485310 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
931417 usd
CY2023Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
1164685 usd
CY2022Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
676888 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
297805 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
756250 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1027782 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1077218 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1079038 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
665434 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1220576 usd
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
715677 usd
CY2023Q2 us-gaap Liabilities
Liabilities
8516217 usd
CY2022Q2 us-gaap Liabilities
Liabilities
7013465 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Preferred Stock Including Additional Paid In Capital
PreferredStockIncludingAdditionalPaidInCapital
2440 usd
CY2022Q2 us-gaap Preferred Stock Including Additional Paid In Capital
PreferredStockIncludingAdditionalPaidInCapital
2440 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39414493275 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39414493275 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31429380453 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31429380453 shares
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1,500 reverse split
CY2022 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1,500 reverse split
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
39414493 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
31429381 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32773102 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
34394912 usd
CY2023Q2 PHIL Common Stock To Be Issued
CommonStockToBeIssued
22500 usd
CY2023Q2 PHIL Common Stock To Be Cancelled
CommonStockToBeCancelled
35500 usd
CY2022Q2 PHIL Common Stock To Be Cancelled
CommonStockToBeCancelled
35500 usd
CY2023Q2 PHIL Treasury Stock Common And Preferred Shares
TreasuryStockCommonAndPreferredShares
484767 shares
CY2022Q2 PHIL Treasury Stock Common And Preferred Shares
TreasuryStockCommonAndPreferredShares
484767 shares
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
44170 usd
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
44170 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77319372 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71717973 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3035495 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-572591 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8222002 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6543502 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294215 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469963 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25000 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30000 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25000 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30000 usd
CY2023 us-gaap Salaries And Wages
SalariesAndWages
360000 usd
CY2022 us-gaap Salaries And Wages
SalariesAndWages
360000 usd
CY2023 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
95242 usd
CY2022 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
15347903 usd
CY2023 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
464848 usd
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1018651 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
105533 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
203374 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
1025623 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
16929928 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-1000623 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-16899928 usd
CY2023 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
488 usd
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1118195 usd
CY2023 us-gaap Interest Expense
InterestExpense
934872 usd
CY2022 us-gaap Interest Expense
InterestExpense
1592557 usd
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3674139 usd
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3780153 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4608523 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4254515 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5609146 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21154443 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34455935655 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28448615941 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34455935655 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28448615941 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5609146 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21154443 usd
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2455157 usd
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
659514 usd
CY2023 PHIL Net Change Due To Conversion Of Notes
NetChangeDueToConversionOfNotes
-4845007 usd
CY2022 PHIL Net Change Due To Conversion Of Notes
NetChangeDueToConversionOfNotes
-20404740 usd
CY2023 PHIL Fund In Transit
FundInTransit
9500 usd
CY2023 PHIL Increase Decrease In Marketable Securities
IncreaseDecreaseInMarketableSecurities
-126 usd
CY2022 PHIL Increase Decrease In Marketable Securities
IncreaseDecreaseInMarketableSecurities
-384911 usd
CY2023 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-114434 usd
CY2022 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
355860 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-114560 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-29051 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
440 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7284 usd
CY2023 PHIL Increase Decrease In Subfund Obligations
IncreaseDecreaseInSubfundObligations
50000 usd
CY2022 PHIL Increase Decrease In Subfund Obligations
IncreaseDecreaseInSubfundObligations
90500 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
553893 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1062061 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
413604 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
83197 usd
CY2023 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
504899 usd
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
715677 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1522836 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-165404 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1572400 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1545570 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3557 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
410834 usd
CY2023 PHIL Proceeds From Financing Loans
ProceedsFromFinancingLoans
49435 usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
29352 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1087288 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1540795 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1520712 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1107288 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48131 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27448 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67896 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95344 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17765 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67896 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6543502 usd
PHIL Stock Issued During Value Conversions Of Promissory Notes
StockIssuedDuringValueConversionsOfPromissoryNotes
233614 usd
PHIL Stock Issued During Value Exercise Of Warrants
StockIssuedDuringValueExerciseOfWarrants
2395080 usd
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
545710 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6881906 usd
CY2023Q1 PHIL Stock Issued During Value Conversions Of Promissory Notes
StockIssuedDuringValueConversionsOfPromissoryNotes
1576175 usd
CY2023Q1 PHIL Stock Issued During Value Conversions Of Promissory Notes
StockIssuedDuringValueConversionsOfPromissoryNotes
1576175 usd
CY2023Q1 PHIL Stock Issued During Value Shares Issued For Cash
StockIssuedDuringValueSharesIssuedForCash
624865 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
185000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
185000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-8286628 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-8286628 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
974877 usd
CY2023Q2 PHIL Stock Issued During Value Shares Issued For Cash
StockIssuedDuringValueSharesIssuedForCash
919397 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8222002 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8222002 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_802_eus-gaap--NatureOfOperations_zaAkYchHEf79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">NOTE 1</span></b> – <b><span id="xdx_82A_zTz6igFi3dSh">NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHI Group, Inc. (n/k/a Philux Global Group Inc) (the “Company” or “PHI”) (<span style="text-decoration: underline">www.philuxglobal.com</span>) is primarily engaged in mergers and acquisitions, advancing Philux Global Funds, SCA, SICAV-RAIF, a “Reserved Alternative Investment Fund” (“RAIF”) under the laws of Luxembourg, and developing the Asia Diamond Exchange in Vietnam. Besides, the Company provides corporate finance services, including merger and acquisition advisory and consulting services for client companies through our wholly owned subsidiary Philux Capital Advisors, Inc. (formerly PHI Capital Holdings, Inc.) (www.philuxcapital.com<span style="text-decoration: underline">)</span> and invests in selective industries and special situations aiming to potentially create significant long-term value for our shareholders. Philux Global Funds intends to include a number of sub-funds for investment in select growth opportunities in the areas of renewable energy, real estate, infrastructure, healthcare, agriculture and the Asia Diamond Exchange in together with the International Financial Center in Vietnam.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BACKGROUND</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Originally incorporated on June 8, 1982 as JR Consulting, Inc., a Nevada corporation, the Company applied for a Certificate of Domestication and filed Articles of Domestication to become a Wyoming corporation on September 20, 2017. In the beginning, the Company was foremost engaged in mergers and acquisitions and had an operating subsidiary, Diva Entertainment, Inc., which operated two modeling agencies, one in New York and one in California. In January 2000, the Company changed its name to Providential Securities, Inc., a Nevada corporation, following a business combination with Providential Securities, Inc., a California-based financial services company. In February 2000, the Company then changed its name to Providential Holdings, Inc. In October 2000, Providential Securities withdrew its securities brokerage membership and ceased its financial services business. Subsequently, in April 2009, the Company changed its name to PHI Group, Inc. From October 2000 to October 2011, the Company and its subsidiaries were engaged in various transactions in connection with mergers and acquisitions advisory and consulting services, real estate and hospitality development, mining, oil and gas, telecommunications, technology, healthcare, private equity, and special situations. In October 2011, the Company discontinued the operations of Providential Vietnam Ltd., Philand Ranch Limited, a United Kingdom corporation (together with its subsidiaries Philand Ranch - Singapore, Philand Corporation - US, and Philand Vietnam Ltd. - Vietnam), PHI Gold Corporation (formerly PHI Mining Corporation, a Nevada corporation), and PHI Energy Corporation (a Nevada corporation), and mainly focused on acquisition and development opportunities in energy and natural resource businesses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is currently focused on Philux Global Funds, SCA, SICAV-RAIF by launching Philux Global Select Growth Fund and potentially other sub-funds for investment in real estate, renewable energy, infrastructure, agriculture, healthcare and the Asia Diamond Exchange and International Financial Center in Vietnam. In addition, Philux Capital Advisors, Inc. (formerly Capital Holdings, Inc.), a wholly owned subsidiary of the Company, continues to provide corporate and project finance services, including merger and acquisition (M&amp;A) advisory and consulting services for U.S. and international companies. The Company has also formed Philux Global Advisors, Inc. to serve as the investment advisor to Philux Global Funds and other potential fund clients in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had signed agreements to acquire majority equity interests in Kota Construction LLC and Kota Energy Group LLC (“KOTA”) which are engaged in solar energy business (<span style="text-decoration: underline">https://www.kotasolar.com</span>), and Tin Thanh Group, a Vietnamese joint stock company (www.tinthanhgroup.vn) (“TTG”). Whereas the scheduled closing dates for the KOTA and TTG transactions already expired, the Company has continued to discuss with these companies and intends to renegotiate an revised agreement with each of them when the Company successfully closes one or more of the pending asset management agreements and financing with certain investor groups and lenders. In addition, the Company intends to amend the Purchase and Sale Agreement that was originally signed on January 18, 2022 with Five-Grain Treasure Spirits Co., Ltd., a Chinese baiju distiller, to collaborate in launching American-made baiju products through Empire Spirits, Inc., a subsidiary of the Company. The Company is in the process of establishing a subsidiary in the Dubai Multi-Commodities Centre in United Arab Emirates to replace its former subsidiary CO2-1-0 (CARBON) Corp. to continue engaging in carbon emission mitigation using blockchain and crypto technologies. In May 2023, the company signed a business cooperation agreement with SSE Global JSC, a Vietnamese joint stock company, to establish SSE Global Group, Inc., a Wyoming corporation, (<span style="text-decoration: underline">www.sseglobalgroup.com</span>) to commercialize a self-sustainable energy technology. In addition, in June 2023 the Company signed a business cooperation agreement with Saphia Alkali JSC, a Vietnamese joint stock company, to form Sapphire Alkali Global Group in the United States to finance, manufacture, sell and distribute Saphia Alkali’s proprietary products on a worldwide basis. These activities are disclosed in greater detail elsewhere in this report. No assurances can be made that the Company will be successful in achieving its plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zzZ07RnRxT0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zQDKmRXgdU9i">USE OF ESTIMATES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
420 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
546 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5609146 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21154443 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34455935655 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28448615941 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34455935655 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28448615941 shares
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Advertising Expense
AdvertisingExpense
500 usd
CY2022 us-gaap Advertising Expense
AdvertisingExpense
8700 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3035495 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-572591 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zfNyUUllTt8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zz66fzo7Y3Zi">RISKS AND UNCERTAINTIES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, the Company is subject to certain risks and uncertainties. The Company provides its service and receives marketable securities upon execution of transactions. Consequently, the value of the securities received from customers can be affected by economic fluctuations and each customer’s business growth. The actual realized value of these securities could be significantly different than recorded value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
420 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
546 usd
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
32604 usd
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
36161 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
616245 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
615805 usd
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1624775 usd
CY2022Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1574775 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1485310 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
931417 usd
CY2023Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
1164685 usd
CY2022Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
676888 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
297805 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
756250 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1027782 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1077218 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1079038 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
665434 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1220576 usd
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
715677 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8516217 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7013465 usd
CY2023Q2 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
1028095 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
338591 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
117625 usd
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
1164685 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
819038 usd
us-gaap Interest Expense
InterestExpense
158604 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
665434 usd
CY2023Q2 us-gaap Deposits
Deposits
260000 usd
CY2023 PHIL Ownership Percentage Of Subfund Participants
OwnershipPercentageOfSubfundParticipants
0.49 pure
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1624775 usd
CY2022Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1574775 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
44170 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2023 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
The “Variable Conversion Price” shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). “Market Price” means the average Trading Price for the Company’s Common Stock during the ten (10) trading-day period ending one trading day prior to the date the Conversion Notice is sent by the Holder of the Class A Preferred Stock to the Company via facsimile or email (the “Conversion Date”)
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Shares Outstanding
SharesOutstanding
31429380289 shares
CY2023Q2 us-gaap Shares Outstanding
SharesOutstanding
39414493275 shares
CY2015Q1 us-gaap Employee Stock Ownership Plan Esop Number Of Allocated Shares
EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares
1000000 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0118 pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.393 pure
CY2023 us-gaap Interest Expense
InterestExpense
934872 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
488 usd
CY2023 us-gaap Other Expenses
OtherExpenses
3674139 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4608523 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
77319372 usd
CY2023 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
The net operating loss carry forward may be used to reduce taxable income through the year 2036. Net operating loss for carry forwards for the State of California is generally available to reduce taxable income through the year 2026. The availability of the Company’s net operating loss carry-forward is subject to limitation if there is a 50% or more positive change in the ownership of the Company’s stock
CY2023Q2 PHIL Common Stock To Be Issued
CommonStockToBeIssued
22500 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77319372 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8222002 usd

Files In Submission

Name View Source Status
phil-20230630_def.xml Edgar Link unprocessable
0001493152-23-037178-index-headers.html Edgar Link pending
0001493152-23-037178-index.html Edgar Link pending
0001493152-23-037178.txt Edgar Link pending
0001493152-23-037178-xbrl.zip Edgar Link pending
ex21-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-k.htm Edgar Link pending
logo_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
phil-20230630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
phil-20230630_lab.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
phil-20230630_cal.xml Edgar Link unprocessable
phil-20230630_pre.xml Edgar Link unprocessable